<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136365</url>
  </required_header>
  <id_info>
    <org_study_id>SHXD2021CR2103B</org_study_id>
    <nct_id>NCT05136365</nct_id>
  </id_info>
  <brief_title>A Study of Xiongdan Wan Treating Depression</brief_title>
  <official_title>The Efficacy and Safety of Xiongdan Wan on Patients With Major Depressive Disorder : a Single-arm, Non-randomized, Open-label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of&#xD;
      Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang&#xD;
      Hai Mental Health Center. Following a screening period, subjects who meet the entry criteria&#xD;
      will be treated with 450mg Xiongdan Wan pills three times daily for 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score compared with baseline at the end of study.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The main objective is to explore whether Xiongdan Wan improve the MDD symptoms after 8 weeks of treatment, and investigators assess the scale at week 1, 2, 4, 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale （HAMD-17）reduction ratio ≥50% reductive ratio [（Baseline score- Endpoint score）／Baseline score]×100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients in remission at the end of the study will be summarized, Montgomery-Asberg Depression Rating Scale (MADRS) score ≤12 or Hamilton Depression Rating Scale （HAMD-17）≤7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio</measure>
    <time_frame>8 weeks</time_frame>
    <description>MADRS reduction ratio is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Hamilton Depression Rating Scale (HAMD-17) reduction ratio</measure>
    <time_frame>8 weeks</time_frame>
    <description>HAMD-17 reduction ratio is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total score of the Hamilton Anxiety Scale(HAMA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of HAMA is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total score of the Clinical Global Impression scale(CGI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of CGI is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Xiongdan Wan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder. The daily dose (1350mg per day) should be strictly controlled according to the experimental design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiongdan Wan</intervention_name>
    <description>Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.</description>
    <arm_group_label>Xiongdan Wan group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition Text&#xD;
             Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD): a single or&#xD;
             recurrent episode without psychotic features. Codes are as follows: F32.0, F32.1,&#xD;
             F32.2, F33.0, F33.1, F33.2.&#xD;
&#xD;
          2. Outpatients.&#xD;
&#xD;
          3. Male or female subjects aged 18-65 years.&#xD;
&#xD;
          4. HAMD-17 score of the baseline period and screening period is 18-24.&#xD;
&#xD;
          5. Women of childbearing potential must be willing to use acceptable methods of&#xD;
             contraception throughout the study period and the following one month.&#xD;
&#xD;
          6. The patient fully understands and signs the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has survived a suicide attempt or has acute suicidal tendencies (HAMD-17 Item3&#xD;
             ≥3).&#xD;
&#xD;
          2. Comorbidity according to DSM-IV-TR, axis-I except for major depressive disorder.&#xD;
&#xD;
          3. HAMD-17 reduction ratio ≥25% within one week from the screening to the baseline&#xD;
             period.&#xD;
&#xD;
          4. Depressive episode secondary to psychiatric illness or somatic disease.&#xD;
&#xD;
          5. Serious and unstable diseases such as cerebrovascular disease; liver and kidney&#xD;
             disease; disease of internal secretion (abnormal thyroid function); hemopathy;&#xD;
             seizures, or other encephalopathies.&#xD;
&#xD;
          6. History of alcohol or drug abuse over the last 6 months.&#xD;
&#xD;
          7. Allergic history to Xiongdan Wan, or serious drug allergic history.&#xD;
&#xD;
          8. Pregnant or lactating women and women of childbearing potential throughout the study&#xD;
             period; men who have the desire of fertility within six months.&#xD;
&#xD;
          9. Clinically significant changes in ECG or laboratory tests, including &gt;1.5 times the&#xD;
             upper limit of normal liver function; over the limit of normal renal function and&#xD;
             blood sugar; abnormal cardiac troponins; obvious abnormity in the thyroid function.&#xD;
&#xD;
         10. Treatment with modified electroconvulsive therapy (MECT) or repetitive transcranial&#xD;
             magnetic stimulation (rTMS) in the past three months.&#xD;
&#xD;
         11. Treatment with a systematic psychological treatment in the past three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang LI, MD, PHD</last_name>
    <phone>86-21-34773128</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>LI, Huafang</investigator_full_name>
    <investigator_title>Executive Director of MICT</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

